FDA week: HHS launches vaccine injury study, midterms may reshape oversight committees, and patent thickets threaten generics

The Department of Health and Human Services announced a new agency‑wide effort to examine and address injuries that may be linked to vaccines. The initiative will coordinate research across FDA and other HHS components to better understand the scope of vaccine‑related adverse events.

At the same time, analysts note that the upcoming congressional midterm elections could lead to significant turnover on the Senate and House committees that oversee the FDA. Changes in committee leadership may affect the agency’s regulatory agenda and priorities.

A recent JAMA special communication reported a steady rise in the number of patents attached to small‑molecule drugs approved by the FDA over the past 15 years. Most of the growth stems from non‑primary patents, creating dense patent thickets that could make it harder for generic manufacturers to enter the market.